Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
Monte Rosa Therapeutics is seeking a Research Associate to join its Proteomics group in Boston to support hit confirmation and drug target validation. The candidate will develop and run cell-based assays to validate hits from the company’s proteomics-based screening platform.
Monterosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases including oncology, autoimmune, and inflammatory conditions. Utilizing the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology, and proteomics, Monterosa identifies and designs MGDs with unparalleled selectivity, enabling access to a diverse range of validated therapeutic targets. The company boasts an industry-leading pipeline of MGDs, positioning it as a pioneer in precision medicine.
Kymera Therapeutics